Article
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
Clinical lung cancer - 1 Jan 2017
Li Tianhong, Piperdi Bilal, Walsh William V, Kim Mimi, Beckett Laurel A, Gucalp Rasim, Haigentz Missak, Bathini Venu G, Wen Huiyu, Zhou Kaili, Pasquinelli Patricia B, Gajavelli Srikanth, Sreedhara Meera, Xie Xianhong, Lara Primo N, Gandara David R, Perez-Soler Roman
Abstract excerpt
BACKGROUND: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant non-small-cell lung cancer (NSCLC) cells, independent of EGFR (epidermal growth factor receptor) genotype. PATIENTS AND METHODS: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m2 provided...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.